Anji and Population Health Partners Begin Strategic Collaboration to Fight Kidney Disease
October 21, 2022
1 minute read
Anji Pharmaceuticals and Population Health Partners announced a strategic collaboration to accelerate the development of two clinical assets from the Anji pipeline, one of which addresses kidney disease, according to the press release.
“We built Anji to be an agile, asset-centric biopharmaceutical company capable of repeatedly unlocking value from clinical programs where we see high validation and unmet need.“, Brian Hubbard, Ph.D., co-founder and CEO of Anji, said in the statement. “Team up with [Population Health Partners] PHP is clearly one of those “1 + 1 = 3” moments, where everyone’s deep skills will allow Anji to deliver life-changing drugs to patients even faster. »
Anji is conducting a phase 3 trial to explore ANJ900 (delayed release metformin) as an investigational agent to ensure the safe use of metformin in patients with Type 2 diabetes and advanced chronic kidney disease. ANJ900 has previously shown lower blood sugar levels with “only one-third of the plasma concentrations seen with currently labeled formulations of metformin,” according to the press release. The recent collaboration between Anji and PHP was designed to accelerate the development and approval of the ANJ900 for patients with CKD.
Similarly, the collaboration focuses on ANJ908 (pradigastat), a potential treatment for chronic idiopathic constipation.
“Anji has an extraordinary team – and a proven and inspiring leader in Brian. Their ability to unpack the complexities of biology, chemistry, pharmacology and clinical performance so they can recognize high potential value and running effective drug development programs is very impressive,” Clive Meanwell, MD, president and managing partner of PHP, said in the release. “We will leverage PHP’s knowledge and experience to help Anji create value and positively impact prevalent diseases.